CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, today announced positive results from an ...
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today ...
Study results warrant further in vivo in-depth investigation of THIO conjugates as second generation cancer therapies MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results